Agensys

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

[Read More]